Sun Pharmaceuticals' Winlevi Granted Approval for Distribution in Australia

Photo:Representative Image

Sun Pharmaceutical Industries Limited has recently announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi, a clascoterone cream. Winlevi is indicated for topical acne vulgaris in patients 12 years of age and older, as per the company’s regulatory filing.

Hellen de Kloet, Business Head – Western Europe, Australia, and New Zealand, Sun Pharma, expressed her excitement, stating that Winlevi is an exciting addition to their expanding dermatology portfolio of innovative medicines in Australia. She added that Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.

Diana Harbort, President of the Dermatology Division of Cosmo, also expressed her pleasure, stating that they are very pleased that Winlevi will soon be available to patients in Australia. She further added that this is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.

As of 9.17 a.m., Sun Pharmaceutical Industries Ltd. 

(Sun Pharma) traded at ₹1,578.20 on the NSE, up by 0.44 percent. Sun Pharma is the fourth largest specialty generic pharmaceutical company globally, with revenues of US$ 5.4 billion. Supported by 43 manufacturing facilities, they provide high-quality, affordable medicines trusted by healthcare professionals and patients in more than 100 countries across the globe.